DPP4 and type 2 diabetes mellitus: GLP-1R is an important drug target for the treatment of T2DM, and several genetic variants in this gene were associated with a response to the glucose-lowering effect of DPP-4 inhibitors, the efficacy of liraglutide and β cell response to GLP-1 administration [181].